Drug cost avoidance analysis of cancer clinical trials in Spain: a study on cost contributors and their impact.

ABSTRACT:

Objective

Analyze the cost contributors and their impact on the drug cost avoidance (DCA) resulting from cancer clinical trials over the period of 2015-2020 in a tertiary-level hospital in Spain (HCUVA).

Methods

We performed a cross-sectional, observational, retrospective study of a total of 53 clinical trials with 363 patients enrolled. We calculated the DCA from the price of the best standard of care (i.e.: drugs that the institution would otherwise fund). A linear regression model was used to determine cost contributors and estimate their impact.

Results

The total DCA was ~ 4.9 million euros (31 clinical trials; 177 enrollees), representing ~ 30% and ~ 0,05% approximately of the annual pharmaceutical expenditures at the HCUVA and for the Spanish Health System, resp

SUBMITTER: Sanchez Martinez DA 

PROVIDER: S-EPMC9316356 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature